Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer
Open Access
- 28 March 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (3) , e0174658
Abstract
Advanced prostate cancers that are resistant to all current therapies create a need for new therapeutic strategies. One recent innovative approach to cancer therapy is the simultaneous use of multiple FDA-approved drugs to target multiple pathways. A challenge for this approach is caused by the different solubility requirements of each individual drug, resulting in the need for a drug vehicle that is non-toxic and capable of carrying multiple water-insoluble antitumor drugs. Micelles have recently been shown to be new candidate drug solubilizers for anti cancer therapy. This study set out to examine the potential use of multi-drug loaded micelles for prostate cancer treatment in preclinical models including cell line and mouse models for prostate cancers with Pten deletions. Specifically antimitotic agent docetaxel, mTOR inhibitor rapamycin, and HSP90 inhibitor 17-N-allylamino-17-demethoxygeldanamycin were incorporated into the micelle system (DR17) and tested for antitumor efficacy. In vitro growth inhibition of prostate cancer cells was greater when all three drugs were used in combination compared to each individual drug, and packaging the drugs into micelles enhanced the cytotoxic effects. At the molecular level DR17 targeted simultaneously several molecular signaling axes important in prostate cancer including androgen receptor, mTOR, and PI3K/AKT. In a mouse genetic model of prostate cancer, DR17 treatment decreased prostate weight, which was achieved by both increasing caspase-dependent cell death and decreasing cell proliferation. Similar effects were also observed when DR17 was administered to nude mice bearing prostate cancer cells xenografts. These results suggest that combining these three cancer drugs in multi-drug loaded micelles may be a promising strategy for prostate cancer therapy.Keywords
Funding Information
- National Cancer Institute (R01CA140217)
- National Cancer Institute (R21CA195313-A1)
This publication has 32 references indexed in Scilit:
- Luminal Cells Are Favored as the Cell of Origin for Prostate CancerCell Reports, 2014
- Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approachesOncogene, 2013
- Molecular genetics of prostate cancer: new prospects for old challengesGenes & Development, 2010
- Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR PathwayCurrent Cancer Drug Targets, 2009
- Editorial for Theme Section on Polymeric Micelles for Drug DeliveryPharmaceutical Research, 2008
- Cross-Talk Between the Androgen Receptor and the Phosphatidylinositol 3-Kinase/Akt Pathway in Prostate CancerCurrent Cancer Drug Targets, 2007
- Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced CancerClinical Cancer Research, 2007
- Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancerCancer Cell, 2003
- Pathological and molecular aspects of prostate cancerThe Lancet, 2003
- Repression of Heat Shock Transcription Factor HSF1 Activation by HSP90 (HSP90 Complex) that Forms a Stress-Sensitive Complex with HSF1Cell, 1998